News & Events
11. January 2022
Cellin Technologies and Hospital of Reconstructive Surgery collaboration project got 1 155 500 EUR funding from Enterprise Estonia (EAS). The project is funded as part of the European Union’s response to the COVID-19 pandemic
"Use of activated autologous mesenchymal stem cells in the treatment of peripheral vascular diseases"
Aim of the project and results:
The aim of the joint action of the Hospital Of Reconstructive Surgery (HRS) and Cellin Technologies (CT) is to treat patients with critical limb ischemia with a novel cellular drug in a frame of hospital exemption. Drug manufacturing technology involves isolating regenerative cells from a patient's adipose tissue, culturing and treating the cells in a laboratory, and returning them to the same patient. We have started the process of patenting the relevant technology.
The use of this drug is intended for people for whom it is not possible to find a solution by conventional methods and whose symptoms are so severe that the only option is leg amputation. It is necessary to pay attention here to the fact that after amputation of the leg, a large part of patients has lost their ability to move independently. Patients who have their legs amputated above the knee can regain their independent mobility in only 30% of cases. The developed technology is expected to reduce ischemic pain (reduce inflammation in the leg), promote the formation of new blood vessels and save up to 30% of the legs that are amputated today. In the long perspective, this treatment method is cost-effective from the point of view of the Health Insurance.
The safety and efficacy of the treatment shall be assessed during the hospital exemption. The positive outcome of this activity will allow us to advance to Phase I / II of clinical trials with our novel stem cell-based drug. The impact of this project on the goal is directly positive, it is a direct help to carry out one of the crucial steps in achieving the final goal of the companies. The impact of the project on Estonian healthcare system would be undoubtedly great. It would be noticed in the world and would benefit Estonia as a country with a great reputation for biotechnology in the world.
Summary of the project for the public:
The aim of this project is to develop a novel cellular drug for the treatment of ischemic blood vessels. The developed drug is a “piece of art” technology because it is made from the patient's stem cells for each specific case. This technology is based on a patent application filed by us (HRS and CT) which is in the international phase and which has been positively evaluated by experts. This treatment technology can save up to 30% of the legs that are amputated today due to ischemia.
October 18, 2016
Greg McGarrell (UK) holds a seminar:
Status of biotherapeutics in canine and equine medicine - When, where and what to use?
Seminar will be held in Tallinn on October 31, 2016.
June 8-9, 2016
Cellin Technologies was one of the organizers at the International Conference on Cell Therapy and Tissue Engineering: Regenerative Medicine - New Developments
The Conference in Tallinn, Estonia was a successful attempt to bring four parties - researchers, regulators, clinicians and back-up forces together.
August 27-28, 2015
Cellin Technologies was one of the organizers at the International Conference on Cell Therapy and Tissue Engineering: Regenerative Medicine - Challenges and Controversies
In Tallinn, Estonia we heard presentations about regenerative medicine`s challenges and controversies. Such names like Keith March (USA), Paula Salmikangas (FIN), Johannes Boltze (GER), Anne Nossent (NED), Toomas Neuman (EST), Andrus Loog (EST) and Toivo Maimets (EST) are few of the experts who stepped up with their presentations in the conference.
January 21, 2015
Estonian company begins production of treatment to cure colorectal cancer
International Pharmaceutical Industry
Cellin Technologies LLC ‒ a GMP cell therapy products manufacturing company located in Tallinn, Estonia ‒ this week started production of melanoma cell lysate, the critical raw material required for the manufacture of MelCancerVac, the colorectal cancer vaccine developed by DanDrit Biotech.
February 12, 2014
Developing a New Branch of Medicine Cell Therapy in Estonia
Journal for Clinical Studies
A recent announcement from Estonia discussed the launching of the first human stem cell production laboratory in the Baltic States. Behind the lab is a wider initiative, the Estonian Cell Therapy Cluster, with the objective of developing the field of cell therapy.
September 27-28, 2013
Cellin Technologies participated in Symposium in Pärnu:
Cell therapy medicine - a breakthrough in regenerative medicine
In cooperation with the Cell Therapy Cluster, a symposium was held in Pärnu, Estonia. The symposium brought together experts to discuss developments in cell therapy and medicine.
March 28, 2013
Cellin Technologies participated in conference in Tallinn: Stem Cells in a Clinic and in a Laboratory
We heard presentations from Mr Andrus Loog (MD, FESVS, Consultant Vascular Surgeon), Mr Olavi Vasar (MD, FESPS, Consultant Plastic and Vascular Surgeon), Mr Toomas Neuman (PhD, Cell Biologist) and Mr (Jüri Laasik, MD, Chief Medical Manager).